Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity
- PMID: 1976576
- PMCID: PMC1378663
- DOI: 10.1136/gut.31.9.1030
Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity
Abstract
Decreased cell mediated cytotoxicity occurs frequently in inflammatory bowel disease, particularly in patients with active disease. It is not clear, however, whether this decrease is caused by the disease or is a consequence of the medical treatment. In this study we evaluated the effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on the in vitro natural killer cell activity in five patients with inflammatory bowel disease in remission and in four healthy control subjects in a double blind randomised crossover trial preceded and separated by four weeks of treatment with placebo. The natural killer cell activity was significantly impaired in 67% (six of nine subjects) after four weeks' sulphasalazine treatment and tended to be related to subjects with a slow acetylator phenotype. In contrast, 5-aminosalicylic acid treatment caused only a marginal reaction in the natural killer cell activity in 22% (two of nine subjects). The inhibitory effects were found to be reversible since the decreased natural killer cell activity was completely restored after placebo treatment in all subjects. In conclusion, in vivo treatment with sulphasalazine inhibits the in vitro natural killer cell activity and this seems to be mediated by the sulphapyridine moiety. This phenomenon may contribute to the low natural killer cell activity found in patients with active inflammatory bowel disease.
Similar articles
-
Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.Clin Sci (Lond). 1985 Aug;69(2):177-84. doi: 10.1042/cs0690177. Clin Sci (Lond). 1985. PMID: 2866061
-
Increased suppressor cell activity in inflammatory bowel disease.Gut. 1981 Dec;22(12):1025-30. doi: 10.1136/gut.22.12.1025. Gut. 1981. PMID: 6119275 Free PMC article.
-
Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.Gut. 1993 Jun;34(6):788-93. doi: 10.1136/gut.34.6.788. Gut. 1993. PMID: 8100205 Free PMC article.
-
Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?Br J Rheumatol. 1995 Nov;34 Suppl 2:16-9. Br J Rheumatol. 1995. PMID: 8535642 Review.
-
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001. Clin Pharmacokinet. 1985. PMID: 2864155 Review.
Cited by
-
Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression.Immunology. 2001 Aug;103(4):473-8. doi: 10.1046/j.1365-2567.2001.01272.x. Immunology. 2001. PMID: 11529938 Free PMC article.
-
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Gut. 2000 Sep;47(3):410-4. doi: 10.1136/gut.47.3.410. Gut. 2000. PMID: 10940280 Free PMC article.
-
Mechanism of action of 5-arninosalicylic acid.Mediators Inflamm. 1992;1(3):151-65. doi: 10.1155/S0962935192000243. Mediators Inflamm. 1992. PMID: 18475455 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources